Cooper Companies COO · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
60.33
-0.69%
Close of 19 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $11.77bn
- Last close × shares
- Volume
- 2.1m
- Shares, 19 Nov 2026
- Price to earnings
- 34.4
About Cooper Companies
From its filings with the US Securities and Exchange Commission
Cooper Companies is based in San Ramon, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker COO. It is a member of the S&P 500. The SEC classifies its business as ophthalmic goods. In the fiscal year to 31 October 2025, it reported revenue of $4.09bn and net income of $374.9m. At that date it held total assets of $12.39bn and shareholders' equity of $8.24bn. By region, United States accounted for 50.2%, followed by Europe at 30.6% and Rest of World at 19.2%.
The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year.
CooperVision is a global manufacturer providing products for contact lens wearers. CooperVision develops, manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. CooperVision designs its products to address vision challenges such as astigmatism, presbyopia and myopia with a broad collection of spherical, toric and multifocal contact lenses. CooperVision offers contact lenses in materials like silicone hydrogel Aquaform technology. CooperVision also manufactures and markets myopia management products, including the internally developed MiSight 1 day lens, as well as other specialty eyecare products such as orthokeratology (ortho-k) and scleral lenses. In November 2019, the MiSight 1 day contact lens became the first and only product approved by the United States Food and Drug Administration (FDA) for slowing the progression of myopia in children aged 8-12 at the initiation of treatment. CooperVision received approval for use of the MiSight 1 day lens in China from Chinese National Medical Products Administration (NMPA) in August 2021 and in Japan from the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2025.
Quoted from its 10-K, filed 5 Dec 2025. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Oct 2023
- Toric lens $828.7m · 23.1%
- Single-use sphere lens $705.4m · 19.6%
- Office and surgical $689.5m · 19.2%
- Non single-use sphere, other $583.9m · 16.3%
Latest on Cooper Companies
Our reporting
We have not reported on Cooper Companies yet.
Next results
Due on 3 Dec 2026. Analysts expect earnings of 1.07 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Cooper Companies's ticker?
Cooper Companies trades as COO on its US listing, under ISIN US2166485019.
What was Cooper Companies's last closing price?
60.33 on 19 Nov 2026. The figure is in USD and is never converted.
When does Cooper Companies next report results?
Results are expected on 3 Dec 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.